Dernières nouvelles pour Kodiak Sciences (NASDAQ:KOD) Stock

Kodiak Sciences

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Kodiak Sciences Inc

Eastman Kodak Co

KODAL MINERALS PLC by KODAL MINERALS PLC

KODIAK COPPER CORP by KODIAK COPPER CORP.

Kodiak Copper Corp

Kodiak Energy Inc

Kodiak Gas Services Inc

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy and maintains $32 price target.

News

Price Target

Analyst Ratings

CMPX

D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $32 Price Target

Baird analyst William Power maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Neutral and lowers the price target from $38 to $32.

Baird Maintains Neutral on RingCentral, Lowers Price Target to $32

On Monday, Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to variants of the <a href="https://www.benzinga.com/pressreleases/25/02/g43923628/latest-db-oto-results-demonstrate-clinically-meaningful-hearing-improvements-in-nearly-all-childre" target="_blank" rel="noreferrer noopener">otoferlin (OTOF) gene</a>.
Regeneron snapped up DB-OTO through its&nbsp;$109 million acquisition&nbsp;of Decibel Therapeutics <a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/33664344/decibel-therapeutics-stock-soars-on-acquisition-deal-the-details" rel="noreferrer noopener">in August 2023</a>.
Congenital deafness (hearing loss present at birth) affects approximately 1.7 out of every 1,000 children born in the U.S. Approximately half of these cases have genetic causes.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43470883/regenerons-q4-earnings-surpass-estimates-launches-quarterly-dividend-and-additional-stock-buyback-program" rel="noreferrer noopener">Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program</a>
However, otoferlin-related hearing loss is ultra-rare. It is caused by variants in the OTOF gene, which lead to a lack of a functional otoferlin protein critical for communication between the inner ear&#8217;s sensory cells and the auditory nerve.
These include 72-week results showing speech and development progress in the first child dosed at 10 months of age and initial results in 11 children (aged 10 months to 16 years old) – three of whom received DB-OTO bilaterally (in both ears).
Among the 11 participants with at least one post-treatment assessment, 10 demonstrated a notable response, with improved hearing at various decibel hearing levels. Additionally, among five participants with 24-week assessments, three experienced improvements in average hearing thresholds to &#8220;nearly normal&#8221; or normal hearing levels.
One participant did not experience a change from their baseline hearing at 24 weeks post-dosing.
Across all 12 participants, the surgical procedure and DB-OTO were well tolerated and no adverse or serious adverse events were considered related to DB-OTO.
Five of the 12 participants experienced transient post-surgical vestibular adverse events (e.g., nystagmus, nausea, dizziness, vomiting), which resolved within 6 days of dosing.
Price Action: REGN stock closed at $713.25 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/02/43910591/fresh-del-monte-stock-falls-as-q4-sales-earnings-miss-expectations" target="_blank" rel="noreferrer noopener">Fresh Del Monte Stock Falls As Q4 Sales &amp; Earnings Miss Expectations</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

REGN

Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss

Keybanc analyst Sangita Jain maintains KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) with a Overweight and lowers the price target from $70 to $67.

Keybanc Maintains Overweight on KBR, Lowers Price Target to $67

Contracts

AREB

Champion Safe  and Wholly-Owned Subsidiary Of American Rebel Holding Enters A Strategic Partnership With Netwize, To Modernize And Optimize Its Technology Infrastructure

WIIM

SLXN

Silexion therapeutics shares are trading higher after the company announced the completion of its initial study in orthotopic pancreatic cancer models evaluating systemic administration of SIL-204.

TZOO

Travelzoo shares are trading lower following worse-than-expected Q4 reported financial results.

Keybanc analyst Tim Rezvan initiates coverage on Infinity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) with a Overweight rating and announces Price Target of $26.

Initiation

Morgan Stanley Market Vectors Rupee/USD ETN

Keybanc Initiates Coverage On Infinity with Overweight Rating, Announces Price Target of $26

ZONE

CleanCore Solutions shares are trading higher after the company announced it will acquire Sanzonate Europe.

Susquehanna analyst Christopher Stathoulopoulos maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Neutral and raises the price target from $247 to $250.

Susquehanna Maintains Neutral on Hilton Worldwide Holdings, Raises Price Target to $250

CJET

Chijet Motor: Stock Purchase Agreement With Too Express Group & Holders of Too Express's Outstanding Capital Shares To Acquire 80% Of Equity Interests

SOUN

SoundHound AI Announces AI Platform For Restaurants

Tempus AI Inc Files For Offering Of Up To 4.84M Shares Of Class A Common Stock By The Selling Stockholder

TARS

Tarsus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

Keybanc analyst Tim Rezvan downgrades Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) from Overweight to Sector Weight.

Downgrades

CIVI

Keybanc Downgrades Civitas Resources to Sector Weight

Susquehanna analyst Christopher Stathoulopoulos maintains Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) with a Neutral and raises the price target from $80 to $110.

Susquehanna Maintains Neutral on Wyndham Hotels & Resorts, Raises Price Target to $110

NLSP

NLS Pharmaceutics And Kadimastem Collaborated With iTolerance; Complete Pre-IND MEeting With FDA For Type 1 Diabetes Treatment

UCTT

Ultra Clean shares are trading lower after Needham cut its price target on the stock from $44 to $40.

Susquehanna analyst Christopher Stathoulopoulos maintains Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) with a Neutral and raises the price target from $150 to $155.

Susquehanna Maintains Neutral on Hyatt Hotels, Raises Price Target to $155

Stephens &amp; Co. analyst Mike Scialla initiates coverage on Infinity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) with a Overweight rating and announces Price Target of $30.

Stephens & Co. Initiates Coverage On Infinity with Overweight Rating, Announces Price Target of $30

Press Releases

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

Earnings

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Kodiak Sciences to Present at Innovate Retina 2024

Kodiak Sciences to Participate in Upcoming Investor Conferences

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Kodiak Sciences

Actualités

Dernières nouvelles pour Kodiak Sciences (NASDAQ:KOD) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL